NAMS (NewAmsterdam Pharma Co NV) Cash per Share: $5.39 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAMS NewAmsterdam Pharma Co NV NAMS
44 GF Score
Price $27.25
GF Value $11.76
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is NewAmsterdam Pharma Co NV Cash per Share?

NewAmsterdam Pharma Co NV NAMS +1.30% 44 Cash per Share is $5.39 as of Jun. 2026. GuruFocus rates NAMS with a GF Score™ of 44/100 and a GF Value™ of $11.76 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). NewAmsterdam Pharma Co NV's Cash per Share for the quarter that ended in Jun. 2026 was $5.39.

NewAmsterdam Pharma Co NV  (NAS:NAMS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

NewAmsterdam Pharma Co NV Cash per Share Related Terms

NewAmsterdam Pharma Co NV Cash per Share Historical Data

* Premium members only.

The historical data trend for NewAmsterdam Pharma Co NV's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV Cash per Share Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial 0.74 5.74 4.13 7.72 5.56

NewAmsterdam Pharma Co NV Quarterly Data
Dec20 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.57 6.21 5.56 5.45 5.39
NAMS
44GF Score
NewAmsterdam Pharma Co NV NAMS
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NewAmsterdam Pharma Co NV Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

NewAmsterdam Pharma Co NV's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=636.241/114.40
=5.56

NewAmsterdam Pharma Co NV's Cash per Share for the quarter that ended in Jun. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=633.854/117.65
=5.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $5.39 mean?
NewAmsterdam Pharma Co NV (NAMS) has a Cash per Share of $5.39 as of Jun. 2026. Cash per share is the per-share value of a company's available cash. View historical data for NewAmsterdam Pharma Co NV and its competitors.
Is NewAmsterdam Pharma Co NV's Cash per Share too high?
NewAmsterdam Pharma Co NV's current Cash per Share is $5.39. Overall, NewAmsterdam Pharma Co NV has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NewAmsterdam Pharma Co NV's Cash per Share compare to ARQT and IDYA?
NewAmsterdam Pharma Co NV's Cash per Share of $5.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for NewAmsterdam Pharma Co NV and its competitors. NewAmsterdam Pharma Co NV's current Cash per Share is $5.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewAmsterdam Pharma Co NV stock overvalued right now?
Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV (NAMS) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.76, compared to a current price of $27.25 — trading 131.7% above its estimated fair value. The current Cash per Share is $5.39. NewAmsterdam Pharma Co NV's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For NewAmsterdam Pharma Co NV (NAMS), the current Cash per Share is $5.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NewAmsterdam Pharma Co NV (NAMS) Overvalued in 2026?

Based on GuruFocus' analysis, NewAmsterdam Pharma Co NV stock appears to be overvalued. The current stock price of $27.25 is trading 131.7% above its estimated GF Value™ of $11.76. GuruFocus considers NewAmsterdam Pharma Co NV to be Significantly Overvalued.

Key valuation signals for NAMS:

  • Cash per Share: $5.39
  • GF Value™: $11.76 vs. price of $27.25 (131.7% above fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the NAMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NewAmsterdam Pharma Co NV Business Description

Other Exchanges KH6:Germany
Address Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
44GF Score

Get the complete analysis for NAMS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.25
Price
$11.76
GF Value